Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 11Lymphoid 3Head & Neck 2Genitourinary 2Breast 2Sarcoma 1Other hematologic neoplasm 1Gynecologic 1CNS 1

Conditions

Urinary Bladder Neoplasms 1Recurrence 1Prostatic Neoplasms 1Neoplasm Metastasis 1Carcinoma, Transitional Cell 1Carcinoma 1

Interventions

Prednisone 122Docetaxel 118enzalutamide 101pembrolizumab 96Sunitinib 86Leuprolide 84Abiraterone Acetate 83Nivolumab 78Gemcitabine 76bicalutamide 54Radiotherapy 54Goserelin 54Bevacizumab 54Cisplatin 52Magnetic Resonance Spectroscopy 49Everolimus 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 46Sorafenib 40Carboplatin 40Paclitaxel 37Radiosurgery 36atezolizumab 35abiraterone 33pazopanib 32cabozantinib 32Ipilimumab 32Axitinib 30Cyclophosphamide 29Androgen Antagonists 29Radiation 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Vitamin B 12 × Genitourinary × Clear all
NCT00722553 2019-12-17

Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

Acrotech Biopharma Inc.

Phase 2 Completed
30 enrolled 12 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Neoplasm Metastasis, Recurrence

NCT00216099 2016-07-29

Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer

Hoosier Cancer Research Network

Phase 2 Completed
49 enrolled 15 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡